Generalization of modern experience of control against the distribution of counterfeit medicines in highly developed countries
DOI:
https://doi.org/10.24959/uekj.20.21Keywords:
counterfeit medicines, modern experience, control of proliferation, highly developed countriesAbstract
One of the most dangerous forms of counterfeit products is counterfeit medicines. In recent years, there has been a marked increase in the production, trade and consumption of such drugs – often with dangerous and in some cases fatal consequences. The World Health Organization (WHO) receives reports of substandard or counterfeit medicines used in various areas of the health care system, from cancer to contraception. The range of products is counterfeit medicines is not limited to expensive drugs or well-known brands, and is distributed approximately equally between generic drugs and patented products.
Aim. To analyze modern methods of fighting the spread of counterfeit medicines in highly developed countries.
Results. A study of the peculiarities of the organization of state quality control of medicines and pharmaceutical activities in the field of fighting the spread of counterfeit medicines in highly developed countries (USA,Canada,Japan, etc.). Among the methods of counteracting drug falsification and preventing the spread of counterfeit medicines, in the developed economies we studied, the introduction of information technology to collect information about counterfeit medicines, codification of drug packaging, the introduction of software to work in the health care system and directly in pharmacies, raising public awareness about counterfeit medicines.
Conclusions. Factors that contribute to the active spread of counterfeit medicines in developed countries are the uncontrolled activities of online pharmacies, insufficient public awareness of all health risks from the purchase of counterfeit medicines, insufficiently controlled drug supply chains at all stages. The likelihood of an increase in counterfeit medicines acquisition depends on statistical and geospatial factors that should be considered when planning measures to combat counterfeit medicines proliferation. The real state of the counterfeit medicines spread is exacerbated by the fact that none of the countries we studied has signed or ratified the Council of Europe Convention on Counterfeit Medical Products and Similar Crimes Threatening the Health of the Population. Generalization and use of international experience will improve the methods of fighting the drug counterfeiting in Ukraine.References
Gasiorowski-Denis, E. (2014). Nastuplenie na kontrafakt. Available at: https://www.iso.org/ru/news/2014/01/Ref1809.html.
Informatciia o rezultatakh gosudarstvennogo kontrolia (nadzora) v sfere obrashcheniia lekarstvennykh sredstv za 2018 god. (2019). Available at: http://www.roszdravnadzor.ru/i/upload/images/2019/3/18/1552890383.7477–1–30251.pdf.
Falsyfikatsiia likarskykh zasobiv ta perevirky aptek: holovne z praktyky mizhnarodnoi farmatsevtychnoi spilnoty. (2017). Аптека, 41 (1112). Available at: https://www.apteka.ua/article/430840.
Soloviov, O. S. (2019). Sotsialna farmatsiia v okhoroni zdorov’ia, 5 (3), 57-64. doi: https://doi.org/10.24959/sphhcj.19.158.
Soloviov, O. S. (2019). Upravlinnia, ekonomika ta zabezpechennia yakosti u farmatsii, 3 (59), 28-34. doi: https://doi.org/10.24959/uekj.19.24.
Tolochko,V., Medvedieva, Yu. (2012). Farmatsevtychnyi kur’ier, 2, 16-19.
Kovalenko, I.A. (2018). Falsyfikatsiia ta obih falsyfikovanykh likarskykh zasobiv: kryminalno-pravove doslidzhennia. Odesa: Helvetyka, 232.
Avdieiev, O. R. (2015). Orhanizatsiino-pravovyi mekhanizm protydii kontrabandi narkotychnykh rechovyn ta falsyfikovanykh likarskykh zasobiv v YeS. Naukovyi visnyk Uzhhorodskoho natsionalnoho universytetu. Seriia «Pravo», 34 (3), 8.
Shmatenko, O. P., Holub, A. H., Rudenko, V. V., Takhtaulova, N. O. (2018). Viiskova medytsyna Ukrainy, 18 (3), 86-90.
Chart of signatures and ratifications of Treaty 211. Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health. Available at: https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/211/signatures.
Kogda budet vynesen prigovor falsifikatu? Available at: http://pharma.net.ua/publications/articles/22722-kogda-budet-vynesen-prigovor-falsifikatu (дата обращения: 14.05.2020).
Khoseva, E. N., Morozova, T. E. (2013). Kachestvennaia klinicheskaia praktika, 2, 53-58.
Stukina, V., Dognal, I., Shaloun, Ya. (2017). Evraziiskii Soiuz uchenykh, 6 (39), 61-66.
Cvetanovski, F., Asanova, B., Brezovska, K. (2016). Comparative analysis of EU and USAfalsified medicine legislation. Macedonian pharmaceutical bulletin, 62 (suppl), 681–682. Available at: https://core.ac.uk/download/pdf/80818116.pdf#page=681.
Galt, K. A., Fuji, K. T., Kaufman, T. K., Shah, Sh. R. (2019). Health Information Technology Use and Patient Safety: Study of Pharmacists in Nebraska. Pharmacy, 7 (1), 7. doi: https://doi.org/10.3390/pharmacy7010007.
Abrill, Ju. L., Holt, D. W., Wilson, R. R. (2016). Falsified Medicines in the European Union and North America: What are we doing to Protect Public Health? J Pharmacovigil, 4, 3. doi: 10.4172/2329-6887.1000213.
Cuomo, R. E., Mackey, T. K. An exploration of counterfeit medicine surveillance strategies guided by geospatial analysis: lessons learned from counterfeit Avastin detection in the US drug supply chain. Available at: https://bmjopen.bmj.com/content/bmjopen/4/12/e006657.full.pdf.
Counterfeit Medicine InAmerica: 9th Annual Drug Abuse Symposium October 29, 2018.
Almuzaini, T., Sammons, H., Choonara, I.(2014). Quality of medicines in Canada: a retrospective review of risk communication documents (2005-2013). BMJ Open, 4, e006088. doi: 10.1136/bmjopen-2014-006088.
Counterfeit medications a growing problem in Canada, warns new report. (2018). Available at: https://www.ctvnews.ca/health/counterfeit-medications-a-growing-problem-in-canada-warns-new-report-1.3795239.
Bloomberg. Available at: https://www.bloomberg.com/.
Lai, C. W., Chan, W. K. (2013). Legislations combating counterfeit drugs in Hong Kong. Hong Kong Med J, 19, 286–93. doi: 10.12809/hkmj133841.
Pharmacy & poisons board of Hong Kong. Available at: https://www.ppbhk.org.hk/eng/index.html.
Hensey, C. C., Gwee, A. (2016). Counterfeit drugs: an Australian perspective. MJA, 204 (9). doi: 10.5694/mja16.00105.
May, C. (2019). Counterfeit medicines — fake drugs and falsified medicines — are endangering lives. Available at: https://www.pharmout.net/counterfeit-medications-global-statistics/.
Alfadl, A. A., Ibrahim, M. I. M., Maraghi, F., Mohammad, Kh. S. (2018). General Public and Community Pharmacists Perception on Counterfeit Medicines: A Preliminary Cross-sectional Study in Qatar. J Clin Diagn Res, 12 (1). doi: 10.7860/JCDR/2018/28451.11136.
Alfadl, A. A. R., Ibrahim, M. I. M., Maraghi, F. A., Mohammad, Kh. S. (2016). An Examination of Income Effect on Consumers’ Ethical Evaluation of Counterfeit Drugs Buying Behaviour: A Cross-Sectional Study in Qatarand Sudan. J Clin Diagn Res, 10 (9), IC01–IC04. doi: 10.7860/JCDR/2016/19526.8410.
Daisaku, Sato. (2014). Counterfeit medicines--Japanand the world. Yakugaku Zasshi, 134 (2), 213-222. doi: 10.1248/yakushi.13-00230-3.
Almuzaini, T., Sammons, H., Choonara, I.(2013). Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001–2011). BMJ Open, 3, e002924. doi: 10.1136/bmjopen-2013-002924.
Houlton, S. (2018). Tackling the problem of falsified medicines in the UK. Prescriber, 29 (7), 33-35. doi: https://doi.org/10.1002/psb.1690.
Robles, Y. R., Casauay, J. F. C., Bulatao, B. P. I. (2016). Addressing the Barriers to Effective Monitoring, Reporting and Containment of Spurious/Substandard/Falsely-labelled/ Falsified/Counterfeit Medical Products through Sustainable Multi-stakeholder Collaboration and Community/Consumer-based Interventions. A report prepared for the Medicines Transparency Alliance.Philippines, 94.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).